AZD5305 CAS No.:2589531-76-8

AZD5305: A Revolutionary Solution for Effective Diabetes Management

As the world grows more health-conscious, the demand for drugs and treatments that help manage chronic medical conditions is on the rise. One of these chronic conditions is diabetes, which affects over 400 million people globally. It is a dangerous condition with severe long-term consequences such as neuropathy, retinopathy, nephropathy, and cardiovascular diseases. Diabetes management requires a combination of medical treatment, lifestyle modifications, and self-care, making it a somewhat difficult condition to manage.

Thanks to advances in research and development, a new drug, AZD5305, has emerged as a promising solution for diabetes management. Developed by AstraZeneca, AZD5305 is a PPARδ receptor agonist that activates PPARδ, a protein involved in glucose and lipid metabolism. As a result, AZD5305 helps improve whole body lipid metabolism, muscle function, and insulin sensitivity, ultimately leading to reduced blood sugar levels.

AZD5305 CAS No.:2589531-76-8 has entered clinical trials, showing promising results in managing type 2 diabetes effectively. It is primarily designed for use in people with type 2 diabetes who are struggling to manage their blood sugar levels despite being on existing oral medication. The drug's mechanism of action is unique, and it is well-tolerated and has few significant side effects.

The drug's effectiveness in humans is backed by a preclinical study in rats, where the drug lowered the animals' blood sugar levels and improved insulin sensitivity. These effects were observed in a dose-dependent manner, meaning the higher the dose, the higher the effect. In a clinical trial of AZD5305 in healthy individuals, the drug increased lipid oxidation, energy expenditure, and insulin sensitivity.

AZD5305 is different from other diabetes medications currently on the market, such as sulfonylureas, DPP-4 inhibitors, and GLP-1 agonists. Sulfonylureas stimulate insulin production from pancreatic beta cells, DPP-4 inhibitors increase GLP-1 levels, and GLP-1 agonists increase insulin secretion, lower glucagon secretion, and delay gastric emptying. AZD5305, on the other hand, improves insulin sensitivity without possessing such mechanisms.

The safety of AZD5305 has been demonstrated in clinical trials, with no significant negative side effects reported. The drug did not cause hypoglycemia or adversely affect liver function, making it a safe and effective choice for treating diabetes.

In conclusion, AZD5305 is a promising new diabetes drug that offers a unique mechanism of action that helps improve insulin sensitivity, lipid metabolism, and muscle function. It can be used in conjunction with existing oral diabetes medication to manage blood sugar levels in people with type 2 diabetes who are struggling to maintain ideal blood sugar control. The drug is safe and well-tolerated, making it an excellent choice for use in diabetes management. With AZD5305, managing diabetes is now more comfortable and safer than ever before.

Chemical Structure : AZD5305

CAS No.: 2589531-76-8

 

AZD5305(AZD-5305)

Catalog No.: URK-V2324  Only Used For Lab.

AZD5305 (AZD-5305) is a potent, selective, orally active PARP1 inhibitor (IC50=3 nM) and PARP1-DNA trapper.

Biological Activity

AZD5305 (AZD-5305) is a potent, selective, orally active PARP1 inhibitor (IC50=3 nM) and PARP1-DNA trapper.
AZD5305 is highly selective for PARP1 over other PARP family members (PARP2 IC50=1.4 uM), with good secondary pharmacology and physicochemical properties and excellent pharmacokinetics in preclinical species.
AZD5305 reduced effects on human bone marrow progenitor cells in vitro, showed excellent in vivo efficacy in a BRCA mutant HBCx-17 PDX model.

Physicochemical Properties

References

1. Jeffrey W Johannes, et al. J Med Chem. 2021 Oct 14;64(19):14498-14512.

URK-V2324_COA

URK-V2324_SDS

URK-V2324_TDS

 

Note: All products of Ureiko are only used for scientific research or drug certificate declaration, and we do not provide products and services for any personal use!

Why choose us?

• Our company culture is based on innovation, integrity, and excellence.
• We hope to have win-win business relationships with you, and create a better tomorrow.
• Our company is registered and certified to ensure compliance with industry standards.
• With a pragmatic attitude and strong ability, we continue to provide satisfactory products and services to our new and old customers.
• Our products are in high demand among researchers and scientists around the world.
• In line with our corporate philosophy, we are sincerely committed to the social responsibility that accompanies running a business.
• Our products are backed by a satisfaction guarantee to give our customers peace of mind.
• We use our superb R&D design and advanced production technology to improve our AZD5305 CAS No.:2589531-76-8, and at the same time combine perfect after-sales service to vigorously develop domestic and foreign markets.
• Our products are made to withstand rigorous testing and use, ensuring accurate results every time.
• We shoulder the corporate development mission of "achieving customers, employees, investors' wishes, and social responsibility". We gain insight into the essential needs of consumers and provide better choices with small changes. At the same time, we create a fair, reasonable, and respectful atmosphere for corporate partners, employees, and their families.

Hot Tags: azd5305 cas no.:2589531-76-8, China azd5305 cas no.:2589531-76-8, agonists for chemokine activation, nf-?b pathway ubiquitination analysis, epigenetic library for epigenetic adaptation, nf b pathway metabolomics, inhibitors for tissue engineering, agonists for polyclonal antibody activation